• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 3. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Chlorobenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Chlorobenzenes

Methyl 3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl)acrylate: A Comprehensive Overview

Methyl 3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl)acrylate (CAS no. 105392-26-5) is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and biomedicine. This compound, characterized by its intricate molecular structure, exhibits a unique combination of functional groups that make it a versatile intermediate in the synthesis of various bioactive molecules. The presence of both cyclopropylamino and benzoyl moieties, coupled with halogen substituents, imparts distinct reactivity and binding properties that are highly valuable in drug discovery and development.

The< strong>cyclopropylamino group in Methyl 3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl)acrylate contributes to its stability and structural integrity, making it an excellent candidate for further functionalization. This feature is particularly advantageous in the design of protease inhibitors and other enzyme-targeted therapeutics, where structural rigidity can enhance binding affinity. Additionally, the< strong>benzoyl moiety serves as a key pharmacophore, facilitating interactions with biological targets such as receptors and enzymes. The dual functionality of this compound positions it as a promising building block for novel drug candidates.

The< strong>2,4-dichloro-5-fluorobenzoyl substituent further enhances the compound's potential utility by introducing both electron-withdrawing and electron-donating effects. This balance of electronic properties can modulate the reactivity of the molecule, allowing for precise control during synthetic transformations. In recent years, there has been growing interest in halogenated aromatic compounds due to their enhanced bioavailability and metabolic stability. Methyl 3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl)acrylate aligns with this trend, offering a valuable tool for medicinal chemists.

In the context of contemporary pharmaceutical research, Methyl 3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl)acrylate has been explored in several cutting-edge studies. For instance, researchers have leveraged its structural features to develop novel inhibitors targeting viral proteases. The cyclopropylamino group's ability to mimic natural amino acid residues has been exploited to create highly specific binding sites. Furthermore, the benzoyl moiety has been shown to enhance solubility and cell permeability, critical factors for drug efficacy. These findings underscore the compound's potential in addressing unmet medical needs.

The< strong>acrylate functional group in Methyl 3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl)acrylate offers additional synthetic versatility. Acrylates are well-known for their ability to undergo Michael additions and other nucleophilic reactions, enabling the facile introduction of diverse molecular fragments. This property has been harnessed in the development of conjugates that combine multiple therapeutic agents into a single entity. Such strategies are particularly relevant in oncology and immunotherapy, where combination therapies are increasingly recognized as effective modalities.

Recent advances in computational chemistry have further highlighted the significance of Methyl 3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl)acrylate. Molecular modeling studies have demonstrated its potential as a scaffold for designing small-molecule inhibitors with improved pharmacokinetic profiles. By integrating experimental data with computational predictions, researchers can optimize the compound's structure to enhance target engagement while minimizing off-target effects. This interdisciplinary approach exemplifies the modern paradigm shift towards precision medicine.

The< strong>CAS no. 105392-26-5 designation ensures unambiguous identification and traceability of this compound throughout its lifecycle. Regulatory agencies and academic institutions rely on such standardized identifiers to maintain consistency in research documentation and commercial distribution. The robustness of this nomenclature system is crucial for ensuring reproducibility and collaboration across global scientific communities.

In conclusion, Methyl 3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl)acrylate represents a compelling example of how structural complexity can be leveraged to develop innovative therapeutic agents. Its unique combination of functional groups makes it a valuable intermediate in drug discovery programs targeting a wide range of diseases. As research continues to evolve, this compound is likely to play an increasingly important role in shaping the future of pharmaceutical chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)